It seems odd to hear Bert Vogelstein talk about failure. He is, after all, widely recognized as a resolute pioneer of cancer research, and is co-director, with Ken Kinzler, of the Ludwig Center at the ... STAT: Six months after launch, Bert Vogelstein’s latest blood testing startup gets acquired for $450 million Six months after launch, Bert Vogelstein’s latest blood testing startup gets acquired for $450 million Benzinga.com: STAT+: Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein's lab A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of lauded cancer researcher Bert Vogelstein’s lab.

Understanding the Context

The Boston-based company, ... STAT+: Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein's lab Bert Vogelstein has an unusual complaint about the humans whose genetic defects he studies: "We're diploid." That can make it difficult to detect mutations in individuals who are heterozygous at ... One day in the early 1990s, Bert Vogelstein was showing fellow cancer researcher Sandy Markowitz around his lab at the Johns Hopkins Medical Institutions in Baltimore. "Suddenly, from halfway across ...

Key Insights